Bayesian estimates of the incidence of rare cancers in Europe

The RACECAREnet Working group

Research output: Contribution to journalArticle

Abstract

Background: The RARECAREnet project has updated the estimates of the burden of the 198 rare cancers in each European country. Suspecting that scant data could affect the reliability of statistical analysis, we employed a Bayesian approach to estimate the incidence of these cancers. Methods: We analyzed about 2,000,000 rare cancers diagnosed in 2000–2007 provided by 83 population-based cancer registries from 27 European countries. We considered European incidence rates (IRs), calculated over all the data available in RARECAREnet, as a valid a priori to merge with country-specific observed data. Therefore we provided (1) Bayesian estimates of IRs and the yearly numbers of cases of rare cancers in each country; (2) the expected time (T) in years needed to observe one new case; and (3) practical criteria to decide when to use the Bayesian approach. Results: Bayesian and classical estimates did not differ much; substantial differences (>10%) ranged from 77 rare cancers in Iceland to 14 in England. The smaller the population the larger the number of rare cancers needing a Bayesian approach. Bayesian estimates were useful for cancers with fewer than 150 observed cases in a country during the study period; this occurred mostly when the population of the country is small. Conclusion: For the first time the Bayesian estimates of IRs and the yearly expected numbers of cases for each rare cancer in each individual European country were calculated. Moreover, the indicator T is useful to convey incidence estimates for exceptionally rare cancers and in small countries; it far exceeds the professional lifespan of a medical doctor.

Original languageEnglish
Pages (from-to)95-100
Number of pages6
JournalCancer Epidemiology
Volume54
DOIs
Publication statusPublished - Jun 1 2018

Fingerprint

Incidence
Neoplasms
Bayes Theorem
Population
Iceland
England
Registries

Keywords

  • Bayesian analysis
  • European countries
  • Incidence
  • Population-based cancer registries
  • Rare cancer

ASJC Scopus subject areas

  • Epidemiology
  • Oncology
  • Cancer Research

Cite this

Bayesian estimates of the incidence of rare cancers in Europe. / The RACECAREnet Working group.

In: Cancer Epidemiology, Vol. 54, 01.06.2018, p. 95-100.

Research output: Contribution to journalArticle

The RACECAREnet Working group. / Bayesian estimates of the incidence of rare cancers in Europe. In: Cancer Epidemiology. 2018 ; Vol. 54. pp. 95-100.
@article{f6f150e6e6d54690b5593d411fb94194,
title = "Bayesian estimates of the incidence of rare cancers in Europe",
abstract = "Background: The RARECAREnet project has updated the estimates of the burden of the 198 rare cancers in each European country. Suspecting that scant data could affect the reliability of statistical analysis, we employed a Bayesian approach to estimate the incidence of these cancers. Methods: We analyzed about 2,000,000 rare cancers diagnosed in 2000–2007 provided by 83 population-based cancer registries from 27 European countries. We considered European incidence rates (IRs), calculated over all the data available in RARECAREnet, as a valid a priori to merge with country-specific observed data. Therefore we provided (1) Bayesian estimates of IRs and the yearly numbers of cases of rare cancers in each country; (2) the expected time (T) in years needed to observe one new case; and (3) practical criteria to decide when to use the Bayesian approach. Results: Bayesian and classical estimates did not differ much; substantial differences (>10{\%}) ranged from 77 rare cancers in Iceland to 14 in England. The smaller the population the larger the number of rare cancers needing a Bayesian approach. Bayesian estimates were useful for cancers with fewer than 150 observed cases in a country during the study period; this occurred mostly when the population of the country is small. Conclusion: For the first time the Bayesian estimates of IRs and the yearly expected numbers of cases for each rare cancer in each individual European country were calculated. Moreover, the indicator T is useful to convey incidence estimates for exceptionally rare cancers and in small countries; it far exceeds the professional lifespan of a medical doctor.",
keywords = "Bayesian analysis, European countries, Incidence, Population-based cancer registries, Rare cancer",
author = "{The RACECAREnet Working group} and Laura Botta and Riccardo Capocaccia and Annalisa Trama and Christian Herrmann and Diego Salmer{\'o}n and {De Angelis}, Roberta and Sandra Mallone and Ettore Bidoli and Rafael Marcos-Gragera and Dorota Dudek-Godeau and Gemma Gatta and Ramon Cleries",
year = "2018",
month = "6",
day = "1",
doi = "10.1016/j.canep.2018.04.003",
language = "English",
volume = "54",
pages = "95--100",
journal = "Cancer Epidemiology",
issn = "1877-7821",
publisher = "Elsevier Ltd",

}

TY - JOUR

T1 - Bayesian estimates of the incidence of rare cancers in Europe

AU - The RACECAREnet Working group

AU - Botta, Laura

AU - Capocaccia, Riccardo

AU - Trama, Annalisa

AU - Herrmann, Christian

AU - Salmerón, Diego

AU - De Angelis, Roberta

AU - Mallone, Sandra

AU - Bidoli, Ettore

AU - Marcos-Gragera, Rafael

AU - Dudek-Godeau, Dorota

AU - Gatta, Gemma

AU - Cleries, Ramon

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Background: The RARECAREnet project has updated the estimates of the burden of the 198 rare cancers in each European country. Suspecting that scant data could affect the reliability of statistical analysis, we employed a Bayesian approach to estimate the incidence of these cancers. Methods: We analyzed about 2,000,000 rare cancers diagnosed in 2000–2007 provided by 83 population-based cancer registries from 27 European countries. We considered European incidence rates (IRs), calculated over all the data available in RARECAREnet, as a valid a priori to merge with country-specific observed data. Therefore we provided (1) Bayesian estimates of IRs and the yearly numbers of cases of rare cancers in each country; (2) the expected time (T) in years needed to observe one new case; and (3) practical criteria to decide when to use the Bayesian approach. Results: Bayesian and classical estimates did not differ much; substantial differences (>10%) ranged from 77 rare cancers in Iceland to 14 in England. The smaller the population the larger the number of rare cancers needing a Bayesian approach. Bayesian estimates were useful for cancers with fewer than 150 observed cases in a country during the study period; this occurred mostly when the population of the country is small. Conclusion: For the first time the Bayesian estimates of IRs and the yearly expected numbers of cases for each rare cancer in each individual European country were calculated. Moreover, the indicator T is useful to convey incidence estimates for exceptionally rare cancers and in small countries; it far exceeds the professional lifespan of a medical doctor.

AB - Background: The RARECAREnet project has updated the estimates of the burden of the 198 rare cancers in each European country. Suspecting that scant data could affect the reliability of statistical analysis, we employed a Bayesian approach to estimate the incidence of these cancers. Methods: We analyzed about 2,000,000 rare cancers diagnosed in 2000–2007 provided by 83 population-based cancer registries from 27 European countries. We considered European incidence rates (IRs), calculated over all the data available in RARECAREnet, as a valid a priori to merge with country-specific observed data. Therefore we provided (1) Bayesian estimates of IRs and the yearly numbers of cases of rare cancers in each country; (2) the expected time (T) in years needed to observe one new case; and (3) practical criteria to decide when to use the Bayesian approach. Results: Bayesian and classical estimates did not differ much; substantial differences (>10%) ranged from 77 rare cancers in Iceland to 14 in England. The smaller the population the larger the number of rare cancers needing a Bayesian approach. Bayesian estimates were useful for cancers with fewer than 150 observed cases in a country during the study period; this occurred mostly when the population of the country is small. Conclusion: For the first time the Bayesian estimates of IRs and the yearly expected numbers of cases for each rare cancer in each individual European country were calculated. Moreover, the indicator T is useful to convey incidence estimates for exceptionally rare cancers and in small countries; it far exceeds the professional lifespan of a medical doctor.

KW - Bayesian analysis

KW - European countries

KW - Incidence

KW - Population-based cancer registries

KW - Rare cancer

UR - http://www.scopus.com/inward/record.url?scp=85045722633&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045722633&partnerID=8YFLogxK

U2 - 10.1016/j.canep.2018.04.003

DO - 10.1016/j.canep.2018.04.003

M3 - Article

VL - 54

SP - 95

EP - 100

JO - Cancer Epidemiology

JF - Cancer Epidemiology

SN - 1877-7821

ER -